1. Statistical Procedures for Bioequivalence Studies Using a Standard Two-Treatment Crossover Design, Guidance, Division of Bioequivalence, Office of Generic Drugs, Food and Drug Administration (revision date: 1 July 1992).
2. Investigation of bioavailability and bioequivalence. InThe Rules Governing Medicinal Products in the European Community, Vol. 2, Addendum No. 2, Office for Official Publications of the European Communities, Luxemburg, May 1992, pp. 149–168.
3. S. Hwang, P. B. Huber, M. Hesney and K. C. Kwan. Bioequivalence and interchangeability (letter).J. Pharma. Sci. 67:IV (1978).
4. S. Anderson and W. W. Hauck. Consideration of individual bioequivalence.J. Pharmacokin. Biopharma. 18:259–273 (1990).
5. G. Ekbohm and H. Melander.On Variation, Bioequivalence and Interchangeability, Report 14, Department of Statistics, Swedish University of Agricultural Science, 1990.